Atypical antipsychotics in the EPS-vulnerable patient
Author:
- 1 January 2003
- journal article
- review article
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 28, 39-51
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s diseaseBiological Psychiatry, 2002
- Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's diseaseMovement Disorders, 2000
- Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's diseaseMovement Disorders, 2000
- A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementiaNeurology, 1999
- Quetiapine for the treatment of drug-induced psychosis in Parkinson's diseaseMovement Disorders, 1999
- Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's diseaseNeurology, 1998
- The emergin role of clozapine in the treatment of movement disordersMovement Disorders, 1997
- Risperidone for psychotic and behavioural symptoms in Lewy body dementiaThe Lancet, 1995
- Risperidone in Parkinson's diseaseThe Lancet, 1994
- The Management of the Levodopa PsychosesClinical Neuropharmacology, 1991